Abstract
Psoriatic arthritis (PsA) is a heterogeneous, inflammatory Progressive disease affecting mainly the skeleton and skin, but with several other organ manifestations. The Czech Society of Rheumatology issues recommendations for the treatment of PsA, which in principle are based on the EULAR recommendations from 2020.
The so-called overarching principles are presented, and the therapy is further divided intofour phases (l. to IV.) based on thestep-up principle. The treatment of PsA is based on the application of disease-modifying antirheumatic drugs (DMARDs), which are divided into synthetic and biotogical.
Recently, the spectrum of these drugs has expanded considerably, and inhibitors ofTNF, IL-17,11-12/23, IL-23, PDE4, and JAK are now available for the treatment of PsA. The effectiveness of individual DMARDs on different domains of PsA can be different, and therefore it is atways advisable to choose this drug individually, according to the predominant manifestation.
Individual treatment algorithms regarding the sequence of DMARDs administration are atso discussed, as well as strategies when DMARDs fail, as welt as strategies for inducing permanent remission. The document must be understood as auxiliary materiál for the attending rheumatologist and not as a mandatory procedure.